Eligible patients from two randomized controlled trials ( Phase II OV-@ and Phase III OV-@ ) were able to enroll in open-label extension ( OLE ) study OV-@ beginning in December @ and received clobazam until they discontinued ( mandatory at @years for patients outside the United States ) or until study completion in March @ .